Recent developments in adjuvants for vaccines against infectious diseases.
about
Current understanding of interactions between nanoparticles and the immune systemAn Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for FinfishEnhanced protective immunity of the chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever in pigs by a Salmonella bacterial ghost adjuvantSingle-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigensCarbon nanotubes as vaccine scaffoldsStability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solutionCross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriersMushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling.Advances in the study of HLA-restricted epitope vaccines.Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.Proteomics integrated with Escherichia coli vector-based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase-like protein of Propionibacterium acnes.The future of vaccination as a treatment strategy in dermatological diseases.Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceSurvey of human-use adjuvants.Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.New and emerging vaccination strategies for prevention and treatment of dermatological diseases.Immunization with recombinant Sao protein confers protection against Streptococcus suis infection.Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.Noninvasive delivery technologies: respiratory delivery of vaccines.Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.Immunostimulatory colloidal delivery systems for cancer vaccines.Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c miceCombination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.Recent developments in mucosal vaccines against prion diseases.Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.QS-21: A Potent Vaccine Adjuvant.Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesInfluence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine.Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccinesPromising particle-based vaccines in cancer therapy.Is intranasal vaccination a feasible solution for tuberculosis?
P2860
Q26345204-3CAB212B-FB95-4BAD-B697-5BEF7222A26EQ26777943-76B13533-AD2A-4AEF-88BD-BB965721C10BQ27469061-29602238-1BBA-412F-A301-DBB0199B6C75Q28390624-F7A13E58-8E34-46AF-9557-D69680809E10Q28392532-6B65D32B-E965-4EC9-9363-494B1B0EE880Q30371202-A185CC60-239B-4425-944F-022B6A3F3D5EQ30377224-5F50620B-3B47-433D-89B8-69DCA5640A9AQ30407662-69013F32-59BB-4EBA-852C-E3AB5EABD7F5Q33368131-0393B8C6-9BA0-4C3B-95B9-038620ACF38FQ33714195-5F312E67-6338-4EAF-8656-97C5D54001C9Q33819711-DD78A51D-4BED-4813-81F2-9A783AB38338Q33918915-B4E91D2B-BC3B-42FC-B07D-3C6938D2BA18Q34170130-488ED8E5-E7F7-4EBD-9312-56D4CEC3B5F9Q34183386-E7E804E2-59B3-4C46-97D7-FE6AE9238A29Q34334406-E2244C06-D048-44EB-9F63-9B781A83C4FCQ34368468-04D0A763-1BAA-4B26-A152-6A2BB39A07F0Q34759942-A05AE2AB-39B5-445D-B10B-12899F4D8295Q35015879-D8910343-86DE-4544-BAF5-42C115819AA0Q35091726-DB074D21-AA09-4482-A23D-93CF40CE0118Q35192171-A7EDAB9A-DD75-4623-8D43-53BFFA632FA7Q35665650-81DDFB67-F271-4C87-9CC1-964415199F2DQ35843635-8AB689C1-ACB8-4093-94C6-A4BDB81E91B7Q36097153-21DEFA45-8256-42F7-AB1C-AFE90BCFF0B0Q36228960-1BCBB0A4-3382-4457-BE5E-CA94BBECEBB5Q36328022-3E5C2DB0-9D7A-4B0B-AF8C-EA6CB96821F9Q36349694-6F4028F1-327C-43C2-89B4-C1503DBFADEDQ36391905-4E13C9F4-5D8F-43B9-85DE-74E72E6E792EQ36447615-61E9743A-7621-4019-A47E-525CF902DD47Q36460849-20F89F3D-436A-4D81-8127-DE5107D5D0FCQ36539044-97197C36-5EFF-4960-AE17-33563AA3BA35Q36576750-3B59E3D3-DBA0-499F-A10E-1F9AA8271F07Q36625724-52E2EC99-F4F2-4605-9CBC-25FE0C00C995Q36728797-EC9D5E29-05DB-4D4C-9147-1DFE563461D1Q36898076-EE608333-06F9-4F7B-BA14-9214B045A593Q36920746-6CC2CD0F-71B5-4091-AEE4-EC9715DD07DFQ36972226-6C87FA34-7086-4ACB-8FBD-BDEC9F97A16FQ36994089-64E57026-5CB3-4F44-82C9-BD446E4E31F0Q37190935-C8927D1E-7D11-4B37-8365-02270177D0BDQ37259642-9AD84FD8-59B9-47D3-9AB1-6E9648AF386EQ37316013-6C1C00E8-94FA-481B-BE39-C0F02E91D5EB
P2860
Recent developments in adjuvants for vaccines against infectious diseases.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Recent developments in adjuvants for vaccines against infectious diseases.
@ast
Recent developments in adjuvants for vaccines against infectious diseases.
@en
Recent developments in adjuvants for vaccines against infectious diseases.
@nl
type
label
Recent developments in adjuvants for vaccines against infectious diseases.
@ast
Recent developments in adjuvants for vaccines against infectious diseases.
@en
Recent developments in adjuvants for vaccines against infectious diseases.
@nl
prefLabel
Recent developments in adjuvants for vaccines against infectious diseases.
@ast
Recent developments in adjuvants for vaccines against infectious diseases.
@en
Recent developments in adjuvants for vaccines against infectious diseases.
@nl
P2093
P1433
P1476
Recent developments in adjuvants for vaccines against infectious diseases.
@en
P2093
P356
10.1016/S1389-0344(01)00101-0
P577
2001-10-01T00:00:00Z